Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite — if that is the correct word — was something of a needed break from the stress and uncertainty enveloping us these days. Well, in any event, what now constitutes the usual routine has now returned as we prepare for Zoom calls and deadlines and what-not. So time to get cracking. Here is the latest menu of tidbits to help you get going. May your day be productive, inspiring and safe. …

An arthritis drug that was seen as a promising treatment for some Covid-19 patients delivered disappointing results in clinical studies, STAT explains. The results for the drug, from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), could have an impact not only for their treatment, Kevzara, but also for a similar drug from Roche (RHHBY), Actemra, that is being used off-label in many hospitals. It also may lower the odds that other repurposed medicines used against autoimmune diseases like rheumatoid arthritis will benefit Covid-19 patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!